Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inspire Medical Systems (INSP) Shares Outstanding (Weighted Average) (2017 - 2025)

Inspire Medical Systems' Shares Outstanding (Weighted Average) history spans 9 years, with the latest figure at $29.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 1.33% year-over-year to $29.4 million; the TTM value through Dec 2025 reached $29.4 million, down 1.33%, while the annual FY2025 figure was $29.4 million, 1.33% down from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $29.4 million at Inspire Medical Systems, roughly flat from $29.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $29.8 million in Q4 2024 and bottomed at $27.1 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $29.3 million (2023), against an average of $28.7 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) rose 12.33% in 2021 before it dropped 1.33% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $27.3 million in 2021, then rose by 2.97% to $28.1 million in 2022, then rose by 4.38% to $29.3 million in 2023, then grew by 1.57% to $29.8 million in 2024, then fell by 1.33% to $29.4 million in 2025.
  • Per Business Quant, the three most recent readings for INSP's Shares Outstanding (Weighted Average) are $29.4 million (Q4 2025), $29.5 million (Q3 2025), and $29.6 million (Q2 2025).